Regulation of B cell lymphocyte responses by TLR10
TLR10 调节 B 细胞淋巴细胞反应
基本信息
- 批准号:8223664
- 负责人:
- 金额:$ 38.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-02-01 至 2017-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAntibodiesAntibody FormationAntigensAutoimmune DiseasesAutoimmune ProcessB Cell ProliferationB-Cell ActivationB-Lymphocyte SubsetsB-LymphocytesCell LineageCell MaturationCellsDendritic CellsDevelopmentDisease ProgressionElementsEventFamilyFamily memberGoalsHumanImmuneImmune responseImmune systemImmunoglobulin Class SwitchingImmunoglobulin Switch RecombinationImmunologic ReceptorsIn VitroInfectious AgentInflammatoryKnowledgeLigandsLinkLupusLymphocyteLymphocyte ActivationLymphoid TissueMaintenanceMediatingMicrobeMitogensMonoclonal AntibodiesMusOutputPatientsPlayProcessPropertyPseudogenesPublicationsReceptor ActivationRegulationResearchRoleSeveritiesSignal TransductionSystemic Lupus ErythematosusT cell responseT-Independent AntigensTLR10 geneToll-like receptorsTransgenic MiceVaccine DesignViraladaptive immunityarmgenome wide association studyinhibitor/antagonistlong term memorymeetingsmembermouse genomemouse modelperipheral bloodreceptor functionresearch studyresponsetoolvaccine development
项目摘要
DESCRIPTION (provided by applicant): Toll-like receptors (TLRs) provide a critical link between the innate and adaptive immune system by sensing microbes and inducing dendritic cell maturation events needed for the activation of T cell responses. Additionally, TLR subsets are expressed in B lymphocytes where they have intrinsic activities which include the promotion of antibody production and maintenance of long term memory. Despite considerable research on TLRs the function of TLR10, which is highly expressed in B cells, remains unknown largely due to a lack of identifiable signaling responses and activating ligands. This knowledge gap is exacerbated by the fact that TLR10 is an inactive pseudogene in mice. This proposal overcomes these barriers through the development and use of research tools which include activating anti-TLR10 antibodies and a TLR10 transgenic mouse model. The overarching goal of this proposal is to characterize TLR10 expression and function within the B cell lineage. This goal is addressed through studies which aim: 1) to fully characterize the profile and regulation of TLR10 expression within the human B cell lineage; 2) to characterize the in vitro function of TLR10 in modulating B cell activity; 3) to define the role of TLR10 in the modulating class switch recombination; 4) to examine the role of TLR10 in regulating antigen-specific adaptive immune responses. These studies have considerable implications for the development of vaccines that are effective in humans and for autoimmune conditions such as lupus where dysregulated TLR activity plays a clear B cell intrinsic role.
PUBLIC HEALTH RELEVANCE: Toll-like receptor 10 is an uncharacterized immune receptor that is highly expressed on human B cells. This proposal aims to understand the function of this receptor in regulating B cell responses leading to antibody production. This research is relevant to vaccine design and autoimmune disease.
描述(由申请人提供):toll样受体(TLRs)通过感知微生物和诱导T细胞反应激活所需的树突状细胞成熟事件,在先天免疫系统和适应性免疫系统之间提供关键联系。此外,TLR亚群在B淋巴细胞中表达,它们具有内在活性,包括促进抗体产生和维持长期记忆。尽管对tlr进行了大量研究,但由于缺乏可识别的信号反应和激活配体,TLR10在B细胞中高表达的功能仍然未知。TLR10在小鼠中是一种不活跃的假基因,这一事实加剧了这种知识差距。本研究通过开发和使用包括激活抗TLR10抗体和TLR10转基因小鼠模型在内的研究工具来克服这些障碍。该建议的总体目标是表征TLR10在B细胞谱系中的表达和功能。这一目标是通过以下研究来实现的:1)充分表征TLR10在人类B细胞谱系中的表达特征和调控;2)表征TLR10在体外调节B细胞活性的功能;3)定义TLR10在调制类开关重组中的作用;4)研究TLR10在调节抗原特异性适应性免疫应答中的作用。这些研究对于开发对人类和自身免疫性疾病(如狼疮)有效的疫苗具有重要意义,其中TLR活性失调明显起B细胞内在作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard Ian Tapping其他文献
Richard Ian Tapping的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard Ian Tapping', 18)}}的其他基金
Regulation of B cell lymphocyte responses by TLR10
TLR10 调节 B 细胞淋巴细胞反应
- 批准号:
8414818 - 财政年份:2012
- 资助金额:
$ 38.1万 - 项目类别:
Genetic and molecular basis of host resistance to Yersinia pestis.
宿主对鼠疫耶尔森氏菌的抗性的遗传和分子基础。
- 批准号:
8422971 - 财政年份:2012
- 资助金额:
$ 38.1万 - 项目类别:
Regulation of B cell lymphocyte responses by TLR10
TLR10 对 B 细胞淋巴细胞反应的调节
- 批准号:
8791296 - 财政年份:2012
- 资助金额:
$ 38.1万 - 项目类别:
Genetic and molecular basis of host resistance to Yersinia pestis.
宿主对鼠疫耶尔森氏菌的抗性的遗传和分子基础。
- 批准号:
8303710 - 财政年份:2012
- 资助金额:
$ 38.1万 - 项目类别:
The Role of Host B Lymphocytes in Yersinia Pathogenesis
宿主 B 淋巴细胞在耶尔森氏菌发病机制中的作用
- 批准号:
7173346 - 财政年份:2005
- 资助金额:
$ 38.1万 - 项目类别:
The Role of Host B Lymphocytes in Yersinia Pathogenesis
宿主 B 淋巴细胞在耶尔森氏菌发病机制中的作用
- 批准号:
7006992 - 财政年份:2005
- 资助金额:
$ 38.1万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 38.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 38.1万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 38.1万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 38.1万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 38.1万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 38.1万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 38.1万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 38.1万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 38.1万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 38.1万 - 项目类别: